Advanced glycation end product-specific receptor (RAGE)

The Advanced glycation end product-specific receptor (RAGE) is a multi-ligand transmembrane receptor belonging to the immunoglobulin superfamily (UniProt: P43657). It is primarily recognized for its interaction with advanced glycation end products (AGEs), which are proteins or lipids that become non-enzymatically glycated after exposure to aldose sugars, a process significantly accelerated in hyperglycemic and oxidative stress environments (PubMed: 22541108). Beyond AGEs, RAGE acts as a pattern recognition receptor for various ligands including HMGB1, S100/calgranulins, and amyloid-beta, triggering intracellular signaling pathways like NF-kappaB and MAPK that drive chronic inflammation and tissue damage (PubMed: 30107159). This signaling axis is a critical driver in the pathogenesis of diabetic complications, cardiovascular diseases, and neurodegenerative disorders such as Alzheimer's disease, where RAGE facilitates the transport of amyloid-beta across the blood-brain barrier. Therapeutic strategies focus on small-molecule antagonists or soluble decoy receptors to block RAGE activation and mitigate downstream inflammatory responses. Despite its therapeutic potential, clinical development has faced significant hurdles, most notably the failure of RAGE inhibitors in late-stage clinical trials for Alzheimer's disease due to lack of efficacy.

Other names

Receptor for advanced glycation end productsAGERAdvanced glycation end product-specific receptorRAGE receptor

Competitive antagonism of the RAGE receptor to prevent the binding of AGEs and other ligands (HMGB1, S100 proteins), thereby inhibiting downstream pro-inflammatory signaling cascades such as the NF-kappaB pathway.